Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPREE-HEARING
ACTRN12614000496617Phase 4Active, not recruiting
- Sponsor
- Monash University
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in presbycusis and No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity comparing Aspirin with Placebo (2 arms). Primary endpoint: Hearing threshold shift. Started Apr 2014; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
presbycusisNo canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on ACTRN12614000496617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000496617.